Direct androgen regulation of PDE5 gene or the lack thereof

International Journal of Impotence Research

Volumn 25, Issue 3, 2013, Pages 81-85

  Lin, C S ^a   Xin, Z ^b   Namiki, M ^c   Albersen, M ^d   Muller, D ^e   Lue, T F ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b PEKING UNIVERSITY FIRST HOSPITAL   (China)

^c KANAZAWA UNIVERSITY   (Japan)

^d UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^e JUSTUS LIEBIG UNIVERSITY   (Germany)

Author keywords

androgen; erectile dysfunction; PDE5; penis

Indexed keywords

ANDROGEN; ANDROGEN RECEPTOR; BETA ACTIN; PHOSPHODIESTERASE V;

ANDROGEN THERAPY; CELL DEDIFFERENTIATION; CHROMATIN IMMUNOPRECIPITATION; CORPUS CAVERNOSUM; GENE EXPRESSION; GENE SEQUENCE; GENETIC ASSOCIATION; HORMONAL REGULATION; HUMAN; IMMUNOHISTOCHEMISTRY; LEYDIG CELL; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROMOTER REGION; PROSTATE CANCER; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; SEQUENCE ALIGNMENT; SEQUENCE ANALYSIS; SMOOTH MUSCLE FIBER; SYSTEMATIC REVIEW;

ANDROGENS; ANIMALS; BASE SEQUENCE; CYCLIC NUCLEOTIDE PHOSPHODIESTERASES, TYPE 5; ERECTILE DYSFUNCTION; GENE EXPRESSION REGULATION; HUMANS; LEYDIG CELLS; MALE; MYOCYTES, SMOOTH MUSCLE; ORCHIECTOMY; PENILE ERECTION; PENIS; PHOSPHODIESTERASE INHIBITORS; PROMOTER REGIONS, GENETIC; RATS; RESPONSE ELEMENTS; RNA, MESSENGER; SEQUENCE ALIGNMENT; TRIPTORELIN PAMOATE;

EID: 84881613956     PISSN: 09559930     EISSN: 14765489     Source Type: Journal    
DOI: 10.1038/ijir.2013.11     Document Type: Review

References (69)

1. Litwin MS, Nied RJ, Dhanani N. Health-related quality of life in men with erectile dysfunction. J Gen Intern Med 1998; 13: 159-166.
2. Dorsey P, Keel C, Klavens M, Hellstrom WJ. Phosphodiesterase type 5 (PDE5) inhibitors for the treatment of erectile dysfunction. Expert Opin Pharmacother 2010; 11: 1109-1122.
3. Thomas MK, Francis SH, Corbin JD. Characterization of a purified bovine lung cGMP-binding cGMP phosphodiesterase. J Biol Chem 1990; 265: 14964-14970.
4. Lin CS. Phosphodiesterase type 5 regulation in the penile corpora cavernosa. J Sex Med 2009; 6(Suppl 3): 203-209.
5. Lin CS, Lin G, Lue TF. Cyclic nucleotide signaling in cavernous smooth muscle. J Sex Med 2005; 2: 478-491.
6. Lin CS, Xin ZC, Wang Z, Lin G, Lue TF. Molecular Yin and Yang of erectile function and dysfunction. Asian J Androl 2008; 10: 433-440.
7. Shabsigh R. Testosterone therapy in erectile dysfunction and hypogonadism. J Sex Med 2005; 2: 785-792.
8. Vignozzi L, Corona G, Petrone L, Filippi S, Morelli AM, Forti G et al. Testosterone and sexual activity. J Endocrinol Invest 2005; 28: 39-44.
9. Morelli A, Filippi S, Zhang XH, Luconi M, Vignozzi L, Mancina R. Peripheral regulatory mechanisms in erection. Int J Androl 2005; 28(Suppl 2): 23-27.
10. Seftel AD. Testosterone regulates PDE5 expression and in vivo responsiveness to tadalafil in rat corpus cavernosum. J Urol 2005; 174: 657-658.
11. Morelli A, Vignozzi L, Filippi S, Mancina R, Maggi M. Erectile dysfunction: molecular biology, pathophysiology and pharmacological treatment. Miner Urol Nefrol 2005; 57: 85-90.
12. Gooren LJ, Saad F. Recent insights into androgen action on the anatomical and physiological substrate of penile erection. Asian J Androl 2006; 8: 3-9.
13. Buvat J, Bou Jaoude G. Significance of hypogonadism in erectile dysfunction. World J Urol 2006; 24: 657-667.
14. Shabsigh R, Rajfer J, Aversa A, Traish AM, Yassin A, Kalinchenko SY et al. The evolving role of testosterone in the treatment of erectile dysfunction. Int J Clin Pract 2006; 60: 1087-1092.
15. Greco EA, Spera G, Aversa A. Combining testosterone and PDE5 inhibitors in erectile dysfunction: basic rationale and clinical evidences. Eur J Urol 2006; 50: 940-947.
16. Burnett AL. Molecular pharmacotherapeutic targeting of PDE5 for preservation of penile health. J Androl 2008; 29: 3-14.
17. Gurbuz N, Mammadov E, Usta MF. Hypogonadism and erectile dysfunction: an overview. Asian J Androl 2008; 10: 36-43.
18. Hwang TI, Lin YC. The relationship between hypogonadism and erectile dysfunction. Int J Impot Res 2008; 20: 231-235.
19. Traish AM. Androgens play a pivotal role in maintaining penile tissue architecture and erection: a review. J Androl 2009; 30: 363-369.
20. Yassin AA, Saad F. Testosterone and erectile dysfunction. J Androl 2008; 29: 593-604.
21. Yassin AA, Akhras F, El-Sakka AI, Saad F. Cardiovascular diseases and erectile dysfunction: the two faces of the coin of androgen deficiency. Andrologia 2011; 43: 1-8.
22. Zhang XH, Melman A, Disanto ME. Update on corpus cavernosum smooth muscle contractile pathways in erectile function: a role for testosterone? J Sex Med 2011; 8: 1865-1879.
23. Mazzola CR, Mulhall JP. Impact of androgen deprivation therapy on sexual function. Asian J Androl 2012; 14: 198-203.
24. Faisst S, Meyer S. Compilation of vertebrate-encoded transcription factors. Nucleic Acids Res 1992; 20: 3-26.
25. Lin CS, Chow S, Lau A, Tu R, Lue TF. Human PDE5A gene encodes three PDE5 isoforms from two alternate promoters. Int J Impot Res 2002; 14: 15-24.
26. Lin CS, Lin G, Xin ZC, Lue TF. Expression, distribution and regulation of phosphodiesterase 5. Curr Pharm Des 2006; 12: 3439-3457.
27. Lin CS, Chow S, Lau A, Tu R, Lue TF. Identification and regulation of human PDE5A gene promoter. Biochem Biophys Res Commun 2001; 280: 684-692.
28. Kasper S, Rennie PS, Bruchovsky N, Sheppard PC, Cheng H, Lin L et al. Cooperative binding of androgen receptors to two DNA sequences is required for androgen induction of the probasin gene. J Biol Chem 1994; 269: 31763-31769.
29. Scheller A, Hughes E, Golden KL, Robins DM. Multiple receptor domains interact to permit, or restrict, androgen-specific gene activation. J Biol Chem 1998; 273: 24216-24222.
30. Lin CS, Lau A, Yeh CC, Chang CH, Lue TF. Upregulation of L-plastin gene by testosterone in breast and prostate cancer cells: identification of three cooperative androgen receptor-binding sequences. DNA Cell Biol 2000; 19: 1-7.
31. Bolton EC, So AY, Chaivorapol C, Haqq CM, Li H, Yamamoto KR. Cell- and genespecific regulation of primary target genes by the androgen receptor. Genes Dev 2007; 21: 2005-2017.
32. Massie CE, Adryan B, Barbosa-Morais NL, Lynch AG, Tran MG, Neal DE et al. New androgen receptor genomic targets show an interaction with the ETS1 transcription factor. EMBO Rep 2007; 8: 871-878.
33. Morelli A, Filippi S, Mancina R, Luconi M, Vignozzi L, Marini M et al. Androgens regulate phosphodiesterase type 5 expression and functional activity in corpora cavernosa. Endocrinology 2004; 145: 2253-2263.
34. Zhang XH, Morelli A, Luconi M, Vignozzi L, Filippi S, Marini M et al. Testosterone regulates PDE5 expression and in vivo responsiveness to Tadalafil in rat corpus cavernosum. Eur Urol 2005; 47: 409-416.
35. Zhang XH, Filippi S, Morelli A, Vignozzi L, Luconi M, Donati S et al. Testosterone restores diabetes-induced erectile dysfunction and sildenafil responsiveness in two distinct animal models of chemical diabetes. J Sex Med 2006; 3: 253-264.
36. Filippi S, Morelli A, Sandner P, Fibbi B, Mancina R, Marini M et al. Characterization and functional role of androgen-dependent PDE5 activity in the bladder. Endocrinology 2007; 148: 1019-1029.
37. Harris DE, Warshaw DM, Periasamy M. Nucleotide sequences of the rabbit alphasmooth- muscle and beta-non-muscle actin mRNAs. Gene 1992; 112: 265-266.
38. Traish AM, Toselli P, Jeong SJ, Kim NN. Adipocyte accumulation in penile corpus cavernosum of the orchiectomized rabbit: a potential mechanism for venoocclusive dysfunction in androgen deficiency. J Androl 2005; 26: 242-248.
39. Hayward SW, Baskin LS, Haughney PC, Foster BA, Cunha AR, Dahiya R et al. Stromal development in the ventral prostate, anterior prostate and seminal vesicle of the rat. Acta Anat (Basel) 1996; 155: 94-103.
40. Niu YJ, Ma TX, Zhang J, Xu Y, Han RF, Sun G. Androgen and prostatic stroma. Asian J Androl 2003; 5: 19-26.
41. Stacey P, Rulten S, Dapling A, Phillips SC. Molecular cloning and expression of human cGMP-binding cGMP-specific phosphodiesterase (PDE5). Biochem Biophys Res Commun 1998; 247: 249-254.
42. Lin CS, Lau A, Tu R, Lue TF. Expression of three isoforms of cGMP-binding cGMPspecific phosphodiesterase (PDE5) in human penile cavernosum. Biochem Biophys Res Commun 2000; 268: 628-635.
43. Agha AM, Taha RA. Sildenafil inhibits agonist-evoked rat uterine contractility: influence of guanylyl cyclase inhibition. Eur J Pharmacol 2001; 428: 343-348.
44. Rybalkin SD, Rybalkina IG, Feil R, Hofmann F, Beavo JA. Regulation of cGMPspecific phosphodiesterase (PDE5) phosphorylation in smooth muscle cells. J Biol Chem 2002; 277: 3310-3317.
45. Lin CS, Lin G, Lue TF. Isolation of two isoforms of phosphodiesterase 5 from rat penis. Int J Impot Res 2003; 15: 129-136.
46. Buhimschi CS, Garfield RE, Weiner CP, Buhimschi IA. The presence and function of phosphodiesterase type 5 in the rat myometrium. Am J Obstet Gynecol 2004; 190: 268-274.
47. Khan RN, Hamoud H, Warren A, Wong LF, Arulkumaran S. Relaxant action of sildenafil citrate (Viagra) on human myometrium of pregnancy. Am J Obstet Gynecol 2004; 191: 315-321.
48. Belmonte A, Ticconi C, Dolci S, Giorgi M, Zicari A, Lenzi A et al. Regulation of phosphodiesterase 5 expression and activity in human pregnant and non-pregnant myometrial cells by human chorionic gonadotropin. J Soc Gynecol Invest 2005; 12: 570-577.
49. Dolci S, Belmonte A, Santone R, Giorgi M, Pellegrini M, Carosa E et al. Subcellular localization and regulation of type-1C and type-5 phosphodiesterases. Biochem Biophys Res Commun 2006; 341: 837-846.
50. Ticconi C, Zicari A, Belmonte A, Realacci M, Rao ChV, Piccione E. Pregnancypromoting actions of HCG in human myometrium and fetal membranes. Placenta 2007; 28(Suppl A): S137-S143.
51. Chiossi G, Costantine MM, Betancourt A, Hankins GD, Longo M, Saade GR et al. Does sildenafil citrate affect myometrial contractile response to nifedipine in vitro? Am J Obstet Gynecol 2010; 203: 252. e1-e5.
52. Armagan A, Kim NN, Goldstein I, Traish AM. Dose-response relationship between testosterone and erectile function: evidence for the existence of a critical threshold. J Androl 2006; 27: 517-526.
53. Zhang X, Zang N, Wei Y, Yin J, Teng R, Seftel A et al. Testosterone regulates smooth muscle contractile pathways in the rat prostate: emphasis on PDE5 signaling. Am J Physiol Endocrinol Metab 2012; 302: E243-E253.
54. Lin CS et al. PDE5 expression and function in the lower urinary tract: a critical review. Urology 2013; doi:10.1016/j.urology.2012.11.028 (in press).
55. Traish AM, Park K, Dhir V, Kim NN, Moreland RB, Goldstein I et al. Effects of castration and androgen replacement on erectile function in a rabbit model. Endocrinology 1999; 140: 1861-1868.
56. Palese MA, Crone JK, Burnett AL. A castrated mouse model of erectile dysfunction. J Androl 2003; 24: 699-703.
57. Rogers RS, Graziottin TM, Lin CS, Kan YW, Lue TF. Intracavernosal vascular endothelial growth factor (VEGF) injection and adeno-associated virus-mediated VEGF gene therapy prevent and reverse venogenic erectile dysfunction in rats. Int J Impot Res 2003; 15: 26-37.
58. Antonioli E, Cardoso AB, Carvalho HF. Effects of long-term castration on the smooth muscle cell phenotype of the rat ventral prostate. J Androl 2007; 28: 777-783.
59. Buttyan R, Ghafar MA, Shabsigh A. The effects of androgen deprivation on the prostate gland: cell death mediated by vascular regression. Curr Opin Urol 2000; 10: 415-420.
60. Tek M, Balli E, Cimen B, Efesoy O, Og̈ uz I, Cayan S. The effect of testosterone replacement therapy on bladder functions and histology in orchiectomized mature male rats. Urology 2010; 75: 886-890.
61. Albersen M, Lin G, Fandel TM, Zhang H, Qiu X, Lin CS et al. Functional, metabolic, and morphologic characteristics of a novel rat model of type 2 diabetes-associated erectile dysfunction. Urology 2011; 78: e471-e478.
62. Zhou F, Xin H, Liu T, Li GY, Gao ZZ, Liu J et al. Effects of icariside II on improving erectile function in rats with streptozotocin-induced diabetes. J Androl 2012; 33: 832-844.
63. Liu WJ, Xin ZC, Xin H, Yuan YM, Tian L, Guo YL. Effects of icariin on erectile function and expression of nitric oxide synthase isoforms in castrated rats. Asian J Androl 2005; 7: 381-388.
64. Yang R, Huang YC, Lin G, Wang G, Hung S, Dai YT et al. Lack of direct androgen regulation of PDE5 expression. Biochem Biophys Res Commun 2009; 380: 758-762.
65. Lin CS, Chow S, Lau A, Tu R, Lue TF. Regulation of human PDE5A2 intronic promoter by cAMP and cGMP: identification of a critical Sp1-binding site. Biochem Biophys Res Commun 2001; 280: 693-699.
66. Kotera J, Fujishige K, Imai Y, Kawai E, Michibata H, Akatsuka H et al. Genomic origin and transcriptional regulation of two variants of cGMP-binding cGMPspecific phosphodiesterases. Eur J Biochem 1999; 262: 866-873.
67. Andric SA, Janjic MM, Stojkov NJ, Kostic TS. Testosterone-induced modulation of nitric oxide-cGMP signaling pathway and androgenesis in the rat Leydig cells. Biol Reprod 2010; 83: 434-442.
68. Muller D, Mukhopadhyay AK, Davidoff MS, Middendorff R. Cyclic GMP signaling in rat urinary bladder, prostate, and epididymis: tissue-specific changes with aging and in response to Leydig cell depletion. Reproduction 2011; 142: 333-343.
69. Shigehara K, Sugimoto K, Konaka H, Iijima M, Fukushima M, Maeda Y et al. Androgen replacement therapy contributes to improving lower urinary tract symptoms in patients with hypogonadism and benign prostate hypertrophy: a randomised controlled study. Aging Male 2011; 14: 53-58.